Investigational drug · Phase 2
AB-1005
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PARKINSON DISEASE (Disorder), Parkinson Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AB-1005"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AB-1005", any sponsor or status.
Conditions studied
As listed on its trial records.
- PARKINSON DISEASE (Disorder)
- Parkinson Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "AB-1005" as an intervention, largest first.
- Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)Not yet recruiting
AskBio IncIndustry
NCT07215403 · 18 participants (planned) · Start Nov 2026 · Primary completion Apr 30, 2028
Drug: AB-1005 · For: PARKINSON DISEASE (Disorder)
Sites: Cleveland, Ohio; Columbus, Ohio; Pittsburgh, Pennsylvania · 4 sites in all
- A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)Not yet recruiting
BayerBayer (BAYRY)
NCT07566429 · 8 participants (planned) · Start Jan 25, 2027 · Primary completion Jun 15, 2029
Drug: AB-1005 · For: Parkinson Disease
Sites: Nagoya, Japan; Yokohama, Japan; Toyonaka, Japan · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease.
Van Laar AD, Christine CW, Phielipp N, et al. · Mov Disord 2025
Also in development for PARKINSON DISEASE (Disorder)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.